IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



The Patent Application of

WILLIAMS et al. Atty. Ref.: 550-453

Serial No. 10/622,134 Group: 1646

Filed: July 18, 2003 Examiner: MERTZ, Prema Maria

For: EOTAXIN: EOSINOPHIL CHEMOTACTIC CYTOKINE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

August 11, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

 \boxtimes 1. PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00

37 C.F.R. §§ 1.97 and 1.98: \boxtimes 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. This paper is submitted in accordance with: 冈 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] \Box 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and П a) The required Statement made in item 8 below; or П b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. П 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and П b) The required Statement is stated in item 8 below. П 8. Statement under 37 CFR 1.97(e) П a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information

The following are submitted in the above-identified application in compliance with

Disclosure Statement.

WILLIAMS et al. Serial No. 10/622,134

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

B Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFORM	MATION DISCLOSU	IRE ATTY. DO	OCKET NO.	SERIAL NO.				
CITATION		550-453		10/622,134				
(Use several sheets if necessary)		APPLICANT			<u> </u>			
		WILLIAMS et al.						
		FILING DATE G		GROUP				
AUG 1 1 2005		July 1	8, 2003	1646				
EE	j.	U.S.	PATENT DOCUMENTS					
EXAMINE OF	RADENAS CUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING IF APPRO	DATE OPRIATE
	6,780,973	08/2004	Luster et al.					
		1					 -	
		1						
								
								-
-								
-		+						
		+						
								
								·
		FORE	IGN PATENT DOCUMEN	NTS			TRANS	ATION
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	YES	NO
				I		<u> </u>		
		1 1						
		1						
		_						
	OTHER DOCUM	IENTS (inc	luding Author, Title, Dat	e Pertir	ent na	nas etc	<u> </u>	
		icivio (ilio	ridding Additor, Title, Dat	ic, i citii	iciti pe	iges, etc.		
								
*Examiner			Date Considered	•				
copy of this form	al if reference considered, whether n with next communication to appli	or not citation is in cation.	conformance with MPEP 609; Draw line thro	ough citation if	not in confo			
						Form PTO-FB-	A820 (Also	PTO-1449